| Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism S Lefere, F Tacke JHEP reports 1 (1), 30-43, 2019 | 217 | 2019 |
| Differential effects of selective-and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆ S Lefere, T Puengel, J Hundertmark, C Penners, AK Frank, A Guillot, ... Journal of hepatology 73 (4), 757-770, 2020 | 194 | 2020 |
| Angiopoietin‐2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease S Lefere, F Van de Velde, A Hoorens, S Raevens, S Van Campenhout, ... Hepatology 69 (3), 1087-1104, 2019 | 109 | 2019 |
| Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool L Devisscher, CL Scott, S Lefere, S Raevens, E Bogaerts, A Paridaens, ... Cellular immunology 322, 74-83, 2017 | 102 | 2017 |
| Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease S Lefere, C Van Steenkiste, X Verhelst, H Van Vlierberghe, L Devisscher, ... Cellular and molecular life sciences 73 (18), 3419-3431, 2016 | 64 | 2016 |
| Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice S Raevens, A Geerts, A Paridaens, S Lefere, X Verhelst, A Hoorens, ... Hepatology 68 (2), 634-651, 2018 | 53 | 2018 |
| Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease S Lefere, F Van de Velde, L Devisscher, M Bekaert, S Raevens, ... International Journal of Obesity 41 (8), 1207-1213, 2017 | 47 | 2017 |
| Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges S Lefere, L Devisscher, F Tacke Expert opinion on investigational drugs 29 (2), 89-92, 2020 | 40 | 2020 |
| Bariatric surgery and the liver—Mechanisms, benefits, and risks S Lefere, L Onghena, A Vanlander, Y Van Nieuwenhove, L Devisscher, ... Obesity Reviews 22 (9), e13294, 2021 | 35 | 2021 |
| Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis T Puengel, S Lefere, J Hundertmark, M Kohlhepp, C Penners, ... International Journal of Molecular Sciences 23 (12), 6696, 2022 | 34 | 2022 |
| The neurogliovascular unit in hepatic encephalopathy W Claeys, L Van Hoecke, S Lefere, A Geerts, X Verhelst, ... JHEP Reports 3 (5), 100352, 2021 | 33 | 2021 |
| Angiogenesis in the progression of non-alcoholic fatty liver disease S Lefere, L Devisscher, A Geerts Acta Gastro-Enterologica Belgica 83 (2), 301-307, 2020 | 32 | 2020 |
| The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma B Vanderborght, S Lefere, HV Vlierberghe, L Devisscher Cells 9 (11), 2382, 2020 | 30 | 2020 |
| Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers S Lefere, H Degroote, H Van Vlierberghe, L Devisscher Journal of hepatology 71 (3), 631-633, 2019 | 30 | 2019 |
| Maternal and perinatal risk factors for pediatric non-alcoholic fatty liver disease: A systematic review I Querter, NS Pauwels, R De Bruyne, E Dupont, X Verhelst, L Devisscher, ... Clinical Gastroenterology and Hepatology, 2021 | 28 | 2021 |
| Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model S Van Campenhout, L Tilleman, S Lefere, A Vandierendonck, S Raevens, ... Metabolism 107, 154220, 2020 | 25 | 2020 |
| Combination of sivelestat and N‐acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen‐induced liver injury S Raevens, S Van Campenhout, PJ Debacker, S Lefere, X Verhelst, ... Journal of leukocyte biology 107 (2), 341-355, 2020 | 22 | 2020 |
| Intensive lifestyle management improves steatosis and fibrosis in pediatric non-alcoholic fatty liver disease S Lefere, E Dupont, A De Guchtenaere, S Van Biervliet, SV Velde, ... Clinical Gastroenterology and Hepatology, 2021 | 18 | 2021 |
| Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models H Degroote, S Lefere, A Vandierendonck, B Vanderborght, T Meese, ... Oncotarget 12 (6), 562-577, 2021 | 18 | 2021 |
| Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model B Vanderborght, K De Muynck, S Lefere, A Geerts, H Degroote, X Verhelst, ... Oncotarget 11 (48), 4504, 2020 | 17 | 2020 |
